Source: TNMichele Wilson PhDScience Writer Immuno-transcriptomics is a field of study focused on analyzing gene expression modifications (mRNA signatures) induced by the immune response to various triggers, such as the onset of cancer. Through deep neural network and machine learning, Novigenix are generating mathematical models based on these mRNA signature analyses to predict the onset and progression
LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational
NEW YORK (GenomeWeb) – With a new CEO at its helm, Swiss molecular diagnostic firm Novigenix is developing a new version of Colox, its mRNA-based assay for early colorectal cancer detection that applies next-generation sequencing instead of RT-PCR. The firm began a study earlier this year to validate the assay, which measures cancer-specific transcriptomic
ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief
Mars Bleu, a campaign to raise awareness about colorectal cancer screening You may have heard about Pink October, a month dedicated to breast cancer awareness and screening. If you didn’t know it yet, there is also the national colorectal cancer awareness month; it’s March and it’s called Mars Bleu (Blue March). Colorectal cancer is
Geneva pharmacies engage in the fight against colorectal cancer The campaign “Mars Bleu” (Blue March) is an opportunity to develop a new network and to make screening even more accessible. In March, 20 Geneva’s drug stores partner with Novigenix for the fight against colorectal cancer by promoting different non-invasive screening solutions including the molecular
Colon cancer kills 5 people every day in Switzerland. "An unacceptable reality", said Brian Haschemi, chairman of Novigenix, a biotech start-up at the heart of the Biopôle in Lausanne. Unacceptable because with early detection, colorectal cancer can be cured. Now the second most deadly form of cancer, the eradication of colorectal cancer represents both a